Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an ...

Novartis’ head of drug development Vas Narasimhan talks about the company’s stake in CAR-T immunotherapy. These cell therapies are set to transform treatment of blood cancers – but questions ...

Narasimhan is confident that Novartis will achieve its goal of increasing sales by an average of 5% annually by 2028.

The new accelerated approval covers the use of Scemblix for newly diagnosed patients with Philadelphia chromosome-positive ...

Vas Narasimhan, CEO at Novartis, discusses third-quarter results, and explains the strategy behind development of the company's most in-demand treatments.